United States Drugs for Malaria Market - Size, Share, Status And Forecast, By Players, Types And Applications 2017-2022

Published On:August 3, 2017, 4:47 pm

Drugs for MalariaMalaria disease is caused by a plasmodium parasite, transmitted by the bite of infected mosquitoes. This infectious disease affects humans and other animals. Symptoms typically begin 10 to 15 days after being bitten by the infected mosquito. These symptoms include feeling tired, fever, vomiting, and headaches. In critical cases, it induces seizures, yellow skin, coma, or even death. If Malaria is not appropriately treated, there are huge chances of recurrences even months later.

Request For Sample Of Drugs for Malaria Market Research Report @ https://www.qyresearchgroups.com/request-sample/456789

In those people who have lately survived through the disease, reinfection typically induces milder symptoms. The drugs for malaria include preventive drugs and treatment drugs. There is no vaccine available for malaria. The preventive drugs are not much useful for those who reside in areas where malaria disease exists and usually prescribed only to pregnant women and short-term visitors or travelers. However, the use of preventative medications where malaria-causing mosquitoes are nearby may promote the development of fractional resistance to the disease. Malaria is treated with antimalarial drugs. Their use depends on the severity and type of the illness. These antimalarial drugs include; lumefantrine, artemisinins, amodiaquine, mefloquine or sulfadoxine/pyrimethamine piperaquine and dihydroartemisinin. These drugs are used in various combinations; as prescribed by consulting healthcare professional.

The United States drug for malaria market is predicted to grow significantly during the forecast period of 2017 to 2022 with substantial compound annual growth rate. The growing incidence of the malarial disease is likely to hike the need of the antimalarial medicines and propels the United States drug for malaria market. The growing research and development actions for the innovative medicines and new compounding of drugs owing to resistance by the bacteria to the presently available treatments also expected to fuel the market industry. The firm initiatives were taken by the several state governments and regulatory agencies like Food and Drug Administration (FDA) to trim down the occurrence of malarial disease throughout the United States, these initiatives also anticipated to boost the demand for the anti-malarial treatments, hence driving the market industry over a forecast period. However, the potential side effects of the drugs such as vivid dreams, insomnia, mental clouding, anxiety, and dizziness might hinder the growth of the United States drug for malaria market.

The key market players for the United States drugs for malaria market are Ajanta Pharma Limited, Cipla Limited, Mylan Laboratories Ltd., Sanofi-Aventis, Guilin Pharmaceutical Co., Ltd., Novartis International AG, GlaxoSmithKline Pharmaceuticals Ltd, Ipca Laboratories Limited and F. Hoffmann-La Roche AG. According to types, the market industry is classified as Aryl Aminoalcohol Compounds, Antifolate Compounds and Artemisinin Compounds. By applications, the drugs for malaria market is split into; Prevention, Treatment and Other. Geographically, the United States market antimalarial into regions which are; The Midwest, The West, New England, Southwest, The Middle Atlantic and The South.

Read More…


Research Assistance Research Assistance

We will be happy to help you find what you need. Please write to us: